var data={"title":"Society guideline links: Chronic myeloid leukemia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Society guideline links: Chronic myeloid leukemia</div><p class=\"disclosureLink\"></p><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H945192928\"><span class=\"h1\">Introduction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.</p><p>The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.</p><p>Links to related guidelines are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-myeloproliferative-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Myeloproliferative disorders&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-myelodysplastic-syndromes\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Myelodysplastic syndromes&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-acute-myeloid-leukemia\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute myeloid leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2818217010\"><span class=\"h1\">International</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=24002&amp;token=ve2V0sDq64C26O6nEQvEHuTs6Ej4ds97NAJMMInkg4axvUsu82mTWxi1MAF0AEyizE2eFxp7bsQcPXbB/nupNVPM96uCRlM0eGFBakQa77tkGL5WVJpj0kwTNEhSyPVz&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">World Health Organization (WHO): Classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.12977/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGPa4cBDW4uBa1Smyab1Q1qQ==&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">International BFM Group Study Group (I-BFM-SG): Managing children with chronic myeloid leukaemia (CML) &ndash; Recommendations for the management of CML in children and young people up to the age of 18&nbsp;years</a> (2014)</p><p/><p class=\"headingAnchor\" id=\"H3773721886\"><span class=\"h1\">United States</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf&amp;token=wEsKVFvqlKzpT+qOtddW/0EI3b9twjod2/LFKUj9NsU4ox9FR7jHnAHXjF2BNuwbhfdl/A1d3w3Sha8gGC6Ug68AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology &ndash; Chronic myeloid leukemia</a> (2018)</p><p/><p class=\"headingAnchor\" id=\"H1033764213\"><span class=\"h1\">Europe</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Myeloid-Leukaemia&amp;token=UCM1rVvNHw9AXyLoxaUO88LTlkcSviPUU1rVFi+n6gtw56/lRdf1vQSMn8kocL77G6hp/nvbsRhenxQMCK3cMJE97yFMcdATaeBEVlBzEc03A8fPk6R4c/ZlQExmw1ZR&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">European Society for Medical Oncology (ESMO): Chronic myeloid leukaemia &ndash; Clinical practice guidelines for diagnosis, treatment and follow-up</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.bloodjournal.org/content/122/6/872&amp;token=dP1xGjeZhmfvfB7SwDZ4pVQqT2Q9gPbDKvHppLqCCvrzEh675C7bhNP1Nfg8PfvAplAYcU3Kuf2lmmqxt0VbAQ==&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">European LeukemiaNet (ELN): Recommendations for the management of chronic myeloid leukemia</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.bloodjournal.org/content/118/5/1208.long&amp;token=dP1xGjeZhmfvfB7SwDZ4pVQqT2Q9gPbDKvHppLqCCvoIVmJEHLx/ZS1EGYpzy/TC/HGh4VdUcv8fw6qeqTCu1A==&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">ELN: Recommendations from an expert panel on BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors</a> (2011)</p><p/><p class=\"headingAnchor\" id=\"H2871024760\"><span class=\"h1\">United Kingdom</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta451&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dOScNLbfSr64fA0qlvRmX7m&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">National Institute for Health and Care Excellence (NICE): Technology appraisal guidance on ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta401&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dORgs+1kl+NwmWP5AlENWku&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on bosutinib for previously untreated chronic myeloid leukaemia</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta425&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dPgkWLp2hLzW19wMWt9IJyp&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta426&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dOK9O3YxR7wq7cPpW1xCyLE&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia</a> (2016)</p><p/><p class=\"headingAnchor\" id=\"H1457606398\"><span class=\"h1\">Japan</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://ijhgateway.net/ArticlePage.aspx?DOI=10.1007/s12185-017-2330-1&amp;token=lMZ95jK7j9FWfJIN6wKdfhAwe9EhMK/ZnTGySmsTZCKmYK1Iaxzrvb/bG+0FZLV3wUeXFfKkI2I2pL5frMHfYAn/Z0kMb1OuP2lmwLK7zMs=&amp;TOPIC_ID=117207\" target=\"_blank\" class=\"external\">Japanese Society of Hematology (JSH): Guideline for tumors of hematopoietic and lymphoid tissues &ndash; Leukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN)</a> (2017)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 117207 Version 1.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H945192928\" id=\"outline-link-H945192928\">Introduction</a></li><li><a href=\"#H2818217010\" id=\"outline-link-H2818217010\">International</a></li><li><a href=\"#H3773721886\" id=\"outline-link-H3773721886\">United States</a></li><li><a href=\"#H1033764213\" id=\"outline-link-H1033764213\">Europe</a></li><li><a href=\"#H2871024760\" id=\"outline-link-H2871024760\">United Kingdom</a></li><li><a href=\"#H1457606398\" id=\"outline-link-H1457606398\">Japan</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-myeloid-leukemia\" class=\"medical medical_society_guidelines\">Society guideline links: Acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-myelodysplastic-syndromes\" class=\"medical medical_society_guidelines\">Society guideline links: Myelodysplastic syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-myeloproliferative-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Myeloproliferative disorders</a></li></ul></div></div>","javascript":null}